Axsome Therapeutics (AXSM) EBT (2015 - 2026)

Axsome Therapeutics has disclosed EBT across 12 years of filings, most recently posting -$64.5 million for Q1 2026.

• EBT for Q1 2026 came in at -$64.5 million, down 8.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$188.8 million (up 32.12% YoY), and the FY2025 annual result was -$183.7 million, up 36.02% from the prior year.
• EBT came in at -$64.5 million for Q1 2026 at Axsome Therapeutics, down from -$28.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$8.6 million in Q1 2023 to a low of -$99.0 million in Q4 2023.
• The 5-year median for EBT is -$61.2 million (2022), against an average of -$56.5 million.
• Across the five-year window, EBT surged 78.2% in 2023 and plunged 691.35% in 2024, its largest moves.
• Axsome Therapeutics' EBT stood at -$61.2 million in 2022, then slumped by 61.62% to -$99.0 million in 2023, then climbed by 24.4% to -$74.8 million in 2024, then surged by 62.41% to -$28.1 million in 2025, then plunged by 129.45% to -$64.5 million in 2026.
• The last three EBT figures came in at -$64.5 million (Q1 2026), -$28.1 million (Q4 2025), and -$47.2 million (Q3 2025), per Business Quant data.